Tasos Konidaris - Mar 3, 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/7/2023, 05:00 PM
Previous filing: Mar 3, 2023
Next filing: Mar 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+45.3K	+18.27%		293K	Mar 3, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-45.3K	-25%	$0.00	136K	Mar 3, 2023	Class A Common Stock	45.3K		Direct	F2, F3
transaction	AMRX	Restricted Stock Units	Award	$0	+229K		$0.00	229K	Mar 3, 2023	Class A Common Stock	229K		Direct	F2, F4
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+459K		$0.00	459K	Mar 3, 2023	Class A Common Stock	459K		Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F4	The restricted stock units vest in four equal annual installments beginning on March 3, 2024.
F5	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F6	Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.